key: cord-0263695-20z5t06a authors: Albóniga, Oihane E.; Jimйnez, Daniel; Sбnchez-Conde, Matilde; Vizcarra, Pilar; Ron, Raquel; Herrera, Sabina; Martнnez-Sanz, Javier; Moreno, Elena; Moreno, Santiago; Barbas, Coral; Serrano-Villar, Sergio title: Metabolic snapshot of plasma samples reveals new pathways implicated in SARS-CoV-2 pathogenesis date: 2021-09-29 journal: bioRxiv DOI: 10.1101/2021.09.29.462326 sha: e82db0a1dd6948054dd4fcc59bdcb83f212d436a doc_id: 263695 cord_uid: 20z5t06a Despite of the scientific and human efforts to understand COVID-19, there are questions still unanswered. Variations in the metabolic reaction to SARS-CoV-2 infection could explain the striking differences in the susceptibility to infection and the risk of severe disease. Here, we used untargeted metabolomics to examine novel metabolic pathways related to SARS-CoV-2 susceptibility and COVID-19 clinical severity using capillary electrophoresis coupled to a time-of-flight mass spectrometer (CE-TOF-MS) in plasma samples. We included 27 patients with confirmed COVID-19 early after symptom onset who were prospectively followed and 29 healthcare workers heavily exposed to SARS-CoV-2 but with low susceptibility to infection (‘nonsusceptible’). We found that the metabolite profile was predictive of the study group. We identified a total of 55 metabolites as biomarkers of SARS-CoV-2 susceptibility or COVID-19 clinical severity. We report the discovery of new plasma biomarkers for COVID-19 that provide mechanistic explanations for the clinical consequences of SARS-CoV-2, including mitochondrial and liver dysfunction as a consequence of hypoxemia (citrulline, citrate, and BAIBA), energy production and amino acid catabolism (L-glycine, L-alanine, L-serine, L-proline, L-aspartic acid and L-histidine), endothelial dysfunction and thrombosis (citrulline, L-ADMA, 2-AB, and Neu5Ac), and we found interconnections between these pathways. In summary, in this first report of the metabolomic profile of individuals with severe COVID-19 and SARS-CoV-2 susceptibility by CE-MS, we define several metabolic pathways implicated in SARS-CoV-2 susceptibility and COVID-19 clinical progression that could be developed as biomarkers of COVID-19. 27 early after symptom onset who were prospectively followed and 29 healthcare 28 workers heavily exposed to SARS-CoV-2 but with low susceptibility to infection 29 ('nonsusceptible'). We found that the metabolite profile was predictive of the study 30 group. We identified a total of 55 metabolites as biomarkers of SARS-CoV-2 31 susceptibility or COVID-19 clinical severity. We report the discovery of new plasma 32 biomarkers for COVID-19 that provide mechanistic explanations for the clinical 33 consequences of SARS-CoV-2, including mitochondrial and liver dysfunction as a 34 consequence of hypoxemia (citrulline, citrate, and BAIBA), energy production and (1-5). Other candidate pathways that could be involved in clinical progression include 54 pyrimidine (1,2) and purine (1,6-8) metabolism, fructose, and mannose metabolism (1,7) and carbon metabolism (1, 2, 9) , although the specific mechanism remains 56 unclear. Overall, the necessity to elucidate the global snapshot of biochemical 57 processes behind SARS-CoV-2 infection is still in progress. Metabolomic profiling can be performed by mass spectrometry (MS) coupled to a 59 separation technique such as liquid chromatography (LC-MS), gas chromatography 60 (GC-MS) or capillary electrophoresis (CE-MS). CE-MS is used to study polar and 61 ionizable compounds such as free modified amino acids (MAAs) and "epimetabolites", which are side products of enzyme reactions. These MAAs or the 63 appearance of epimetabolites has been associated with important alterations in 64 cellular, physiological, and pathological processes(10-13). While CE-MS is a powerful 65 method to characterize unknown mechanisms of disease progression, to our 66 knowledge, it has not been used in individuals with COVID-19. Here, we investigated novel metabolic pathways of SARS-CoV-2 susceptibility and 68 COVID-19 clinical progression using CE-MS in longitudinal plasma samples from 69 patients with COVID-19 with different disease severities and in a population of 70 healthcare workers heavily exposed to SARS-CoV-2 but with low susceptibility to 71 infection. General characteristics of the study population 74 We included 63 adults, of whom 27 were in the COVID-19+ group and 36 were in the 75 COVID-19-group, of whom 24 were nonsusceptible. COVID-19+ and susceptible 76 patients were older and had a higher prevalence of comorbidities than COVID-19-77 and nonsusceptible patients. The general characteristics of the study population are 78 described in Table 1 . Validated OPLS-DA models (Fig 3) showed that the longitudinal differences detected 134 for mild and moderate cases were statistically significant (CV-ANOVA p-value < 0.05 135 and R 2 -Q 2 < 0.3). We found 10 metabolites whose abundance differed from baseline 136 to day 8 in mild cases and 7 in moderate cases (VIP ≥ 1 and │p(corr)│ ≥ 0.5), see S1 137 Table) . To visually summarize the metabolite fingerprint associated with COVID-19 disease 148 and SARS-CoV-2 susceptibility, we represented the abundance of the metabolites 149 identified by univariate analysis followed by multivariate statistical analysis as 150 predictors of each condition in heatmaps with hierarchical clustering (Fig 4, Fig S3 and 151 Fig S4) . As shown in the heatmap (Fig 4) , (Tables S2 and S3 Table 2 . Blue color denotes the fold change representing the increase of metabolite abundance and red color represents the decreases (see Table 170 S1 for additional information). To our knowledge, this study is the first to evaluate the plasma metabolomic profile of Apart from phenylalanine, other amino acids (AAs) were found to be significantly different 200 between the groups (Table 2) genes commonly downregulated in multiple organs that led to significant enrichment in 205 pathways related to oxidative phosphorylation and the electron transport chain (17). As the 206 tricarboxylic acid (TCA) cycle is connected to the electron transport chain, they also 207 analyzed genes associated with the TCA cycle. They found that several TCA cycle genes 208 were downregulated and that TCA cycle metabolites were decreased in animal serum (17). Apart from the AAs that lead to intermediates of the TCA cycle that were downregulated in 210 the COVID-19+ group, the significant downregulation of citrate also suggested that SARS- CoV-2 results in inefficient mitochondrial metabolism (18, 19) , which can be interpreted as 212 the metabolic response to impaired oxygenation secondary to lung damage (9). Citrate is a 213 direct TCA cycle metabolite obtained by the action of citrate synthase from oxaloacetate. The gene encoding this enzyme exhibits decreased expression (17). Different genes, proteins and/or metabolites involved in the TCA cycle have been found to be suppressed 216 or downregulated in individuals with 19) . An intriguing finding in our study is the upregulation of 3-aminoisobutyric acid (BAIBA) We also found evidence that SARS-CoV-2 affects metabolic pathways implicated in 263 Impairment of the kynurenine pathway, resulting in reduced tryptophan (Trp) and elevated 264 kynurenine (Kyn) levels associated with COVID-19, has previously been reported (3,7,36). Our data reveal not only the same tendency for Trp and Kyn but also the increasing 266 tendency of the Kyn/Trp ratio with severity. This ratio has previously been associated with 267 renal insufficiency in patients with SARS-CoV-2 and in many other diseases, such as The major strengths of our study include 1) the inclusion of COVID-19 cases in an early to different metabolic consequences. Second, as expected, cases in the severe group were 283 older and had more comorbidities than milder cases, so we considered potential 284 confounders in our statistical approach. Third, in the subgroup analyses separated by clinical severity, the statistical power to detect differences in metabolite abundances was 286 lower due to the smaller sample sizes. In summary, in this work examining for the first time the metabolic changes associated with All reagents, solvents and standards used for sample treatment and subsequent analysis are 300 described in the Supporting Information. Participants without SARS-CoV-2 (COVID-19-group) were asymptomatic subjects with a 312 negative PCR from nasopharyngeal swabs. We considered adults to be "susceptible" when The plasma metabolome was analyzed by using a 7100 capillary electrophoresis (CE) system Hydroxychloroquine, initially found to be significant, was removed from all statistical 596 analysis as it was empirically used to treat COVID19 at the time of sample collection. Plasma metabolomic and lipidomic 431 alterations associated with COVID-19. National Science Review Untargeted metabolomics 434 of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome. 435 medRxiv COVID-19 infection 438 alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI 439 insight Multi-omic Analysis of COVID-19 Severity. Cell systems Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan 444 Pathological Signature of SARS-CoV-2 Infection Automated Diagnosis and Risk Assessment through Metabolomics and Machine Learning. 448 Analytical Chemistry Proteomic and Metabolomic Characterization of 450 COVID-19 Patient Sera Understanding the 452 pathophysiological changes via untargeted metabolomics in COVID-19 patients Omics-Driven Systems Interrogation 455 of Metabolic Dysregulation in COVID-19 Pathogenesis. Cell metabolism Unveiling the 458 Fragmentation Mechanisms of Modified Amino Acids as the Key for Their Targeted 459 Identification. Analytical Chemistry Sarcosine Metabolism in Prostate Cancer Progression Differential effects 464 of arginine methylation on diastolic dysfunction and disease progression in patients with 465 chronic systolic heart failure Epimetabolites: discovering metabolism beyond building and 468 burning Trials and tribulations of 'omics data analysis: assessing quality of 471 SIMCA-based multivariate models using examples from pulmonary medicine. Molecular 472 bioSystems From numbers to a biological sense: How the 474 strategy chosen for metabolomics data treatment may affect final results. A practical example 475 based on urine fingerprints obtained by LC-MS Metabolic reprogramming and 478 epigenetic changes of vital organs in SARS-CoV-2-induced systemic toxicity. JCI insight Implications 481 of central carbon metabolism in SARS-CoV-2 replication and disease severity Metabolomics analysis reveals a modified amino acid metabolism that 486 correlates with altered oxygen homeostasis in COVID-19 patients Acid as a Novel Regulator of Carbohydrate and Lipid Metabolism Aerobic Exercise Leads to Increased Plasma Levels of R-and S-β-Aminoisobutyric Acid in 495 Humans. Frontiers in physiology Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, 497 explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. The Journal of 498 nutrition Asymmetric dimethylarginine (ADMA), 500 symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg 501 paradoxes Nitric oxide and 503 redox mechanisms in the immune response The role of nitric oxide in the regulation of adaptive immune responses Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. The New England journal 510 of medicine Differential metabolomics 512 reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione 513 consumption. The Journal of biological chemistry 2-Aminobutyric acid modulates 515 glutathione homeostasis in the myocardium Patterns of 518 myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular 519 magnetic resonance Sialic acid-specific lectins: occurrence, specificity and 522 function Correlation of serum N-Acetylneuraminic 524 acid with the risk and prognosis of acute coronary syndrome: a prospective cohort study. BMC 525 cardiovascular disorders Serum N-Acetylneuraminic Acid Is Associated 527 with Atrial Fibrillation and Left Atrial Enlargement. Cardiology research and practice Tryptophan catabolism by indoleamine 532 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease The kynurenine 537 pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV Ugandans initiating antiretroviral therapy. The Journal of infectious diseases The specific metabolome 541 profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide 542 pathway and cytosine metabolism. Scientific reports Tryptophan metabolism 544 in chronic inflammatory lung disease. The Journal of laboratory and clinical medicine Interactions between nitric oxide and indoleamine 2,3-dioxygenase. 547 Biochemistry Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional 549 Aspects. International journal of tryptophan research : IJTR Nitric oxide-mediated 552 regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human 553 indoleamine 2,3-dioxygenase. Infection and immunity Acute respiratory distress 555 syndrome: new definition, current and future therapeutic options Interim Operational Considerations for Public Health 559 Management of Healthcare Workers Exposed to or with Suspected or Confirmed COVID-19: 560 non-U.S. Healthcare Settings Method development and validation for rat serum 562 fingerprinting with CE-MS: application to ventilator-induced-lung-injury study. Analytical and 563 bioanalytical chemistry ANOVA-566 simultaneous component analysis (ASCA): a new tool for analyzing designed metabolomics 567 data What Is Analysis of Covariance (ANCOVA) and How 569 to Correctly Report Its Results in Medical Research? Iranian journal of public health Enhancing 573 confidence of metabolite annotation in Capillary Electrophoresis-Mass Spectrometry 574 untargeted metabolomics with relative migration time and in-source fragmentation METLIN: a metabolite mass 577 spectral database. Therapeutic drug monitoring Update of the 579 LIPID MAPS comprehensive classification system for lipids KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research In-585 source fragmentation and correlation analysis as tools for metabolite identification exemplified 586 with CE-TOF untargeted metabolomics = 0.636, and CV-ANOVA p-value = 0.027.